Pegylated interferon may be considered in chronic viral hepatitis e resistant to ribavirin in kidney transplant recipients

0Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.

This artice is free to access.

Abstract

Background: Hepatitis E virus (HEV) may be resistant to immunosuppression reduction and ribavirin treatment in kidney transplant recipients because of mutant strains and severe side effects of ribavirin which conduct to dose reduction. Sofosbuvir efficacy is controversial. Peg-interferon 2 alpha (PEG-IFN) is currently contraindicated due to a high risk of acute humoral and cellular rejection. The present study assessed, for the first time, the effect of PEG-IFN in a kidney transplant recipient infected with HEV. Case presentation: The patient had chronic active HEV that was resistant to immunosuppression reduction and optimal ribavirin treatment. He developed significant liver fibrosis. PEG-IFN was administered for 10 months, and it was well tolerated and did not induce rejection. A sustained virological response was obtained. Conclusions: We conclude that prolonged treatment with PEG-IFN in kidney transplant recipients infected with HEV could be considered as a salvage option.

Cite

CITATION STYLE

APA

Ollivier-Hourmand, I., Lebedel, L., Lecouf, A., Allaire, M., Nguyen, T. T. N., Lier, C., & Dao, T. (2020). Pegylated interferon may be considered in chronic viral hepatitis e resistant to ribavirin in kidney transplant recipients. BMC Infectious Diseases, 20(1). https://doi.org/10.1186/s12879-020-05212-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free